Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Gilead Sciences and raises the price target from $76 to $84.
October 07, 2024 | 6:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Gilead Sciences while increasing the price target from $76 to $84, indicating a positive outlook.
The increase in the price target from $76 to $84 by Barclays suggests a positive outlook for Gilead Sciences, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100